Neurovascular-immune mediator dynamics in migraine: State-dependent effects of caffeine

What Was Tested

This randomized controlled trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.

Migraine is a complex neurovascular disorder involving interactions between trigeminovascular, endothelial, and neuroimmune pathways.

Dysregulation of key mediators-calcitonin gene-related peptide (CGRP), nitric oxide (NO), endothelin-1, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)-is central to its pathophysiology.

Who Took Part

The study group was 327 participants.

PubMed indexes the participants as young adults and adults, both men and women.

A total of 327 participants (174 migraine patients and 153 healthy controls) were included.

Migraine patients were assessed across interictal and ictal phases using a within-subject design.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with CGRP (Calcitonin Gene-Related Peptide) could be set against what happens without it.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

Blood samples were collected at baseline (T0) and 60 min post-intervention (T1).

Mediators were measured using ELISA and analyzed with linear mixed-effects models.

What Was Measured

This study evaluated phase-specific alterations in these mediators and their intra-individual response to caffeine.

Topics PubMed links to this paper include Caffeine, Migraine Disorders, Nitric Oxide, Calcitonin Gene-Related Peptide, Endothelin-1, Tumor Necrosis Factor-alpha and Interleukin-6.

Author keywords: Calcitonin gene-related peptide (CGRP) and Neurovascular mediators.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in 327 participants in people with migraine.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology), a journal based in Italy.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.